News & Events

Redbiotec has rented 200 additional square meters of lab and office space. Till end of Q2 2011 Redbiotec will implement new cutting edge technologies into its leading rePAX® platform, including the ÄKTA avant system (GE Healthcare).

Redbiotec closes deal with Roche. Redbiotec AG, the leader in protein complexes and designer virus-like particles (VLP) enters into a collaboration with Roche, by which it will apply its proprietary technology platform [rePAX®] to an undisclosed discovery area. After having successfully worked for two leading global vaccine players in 2010, the deal with Roche is an additional highlight of a successful year for Redbiotec.

We are proud to announce that in November 1st Dr. Tiago Vicente, joined Redbiotec as purification expert. With his strong background in downstream processing Dr. Vicente will implement specific purification methods and processes for Redbiotec’s new designer VLPs, particularly in the field of Herpesviruses.

Redbiotec obtains a new grant. The grant is a initiative with the Group of Prof. Wilfried Weber, University of Freiburg, to explore further applications of Redbiotec’s REPAX™ technology.

Redbiotec has launched the development of several multi-valent virus-like particles (VLPs) against the Cytomegalovirus (CMV).